WO2002000872A3 - Compositions et methodes pour le traitement ou la detection de pathologies neurodegeneratives - Google Patents

Compositions et methodes pour le traitement ou la detection de pathologies neurodegeneratives Download PDF

Info

Publication number
WO2002000872A3
WO2002000872A3 PCT/FR2001/002058 FR0102058W WO0200872A3 WO 2002000872 A3 WO2002000872 A3 WO 2002000872A3 FR 0102058 W FR0102058 W FR 0102058W WO 0200872 A3 WO0200872 A3 WO 0200872A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
concerns
treating
motor neurons
degenerative diseases
Prior art date
Application number
PCT/FR2001/002058
Other languages
English (en)
Other versions
WO2002000872A2 (fr
Inventor
Ikhlef Ali Ait
Annelies Resink
Fabien Schweighoffer
Original Assignee
Exonhit Therapeutics Sa
Ikhlef Ali Ait
Annelies Resink
Fabien Schweighoffer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exonhit Therapeutics Sa, Ikhlef Ali Ait, Annelies Resink, Fabien Schweighoffer filed Critical Exonhit Therapeutics Sa
Priority to AU2001270691A priority Critical patent/AU2001270691A1/en
Publication of WO2002000872A2 publication Critical patent/WO2002000872A2/fr
Publication of WO2002000872A3 publication Critical patent/WO2002000872A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne le domaine de la biologie, de la génétique et de la médecine. Elle concerne notamment de nouvelles méthodes pour la détection, la caractérisation et/ou le traitement (ou la prise en charge) de pathologies neurodégénératives, notamment de la sclérose latérale amyotrophique. L'invention concerne également des méthodes pour l'identification ou le screening de composés actifs dans ces pathologies. L'invention concerne également les composés, gènes, cellules, plasmides ou compositions utiles pour la mise en oeuvre des méthodes ci-dessus. L'invention décrit notamment le rôle de calcineurine dans ces pathologies et son utilisation comme cible thérapeutique, diagnostique ou expérimentale.
PCT/FR2001/002058 2000-06-29 2001-06-28 Compositions et methodes pour le traitement ou la detection de pathologies neurodegeneratives WO2002000872A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001270691A AU2001270691A1 (en) 2000-06-29 2001-06-28 Compositions and methods for treating or detecting degenerative diseases of the motor neurons

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR00/08407 2000-06-29
FR0008407A FR2810995A1 (fr) 2000-06-29 2000-06-29 Compositions et methodes pour le traitement ou la detection de pathologies neurodegeneratives

Publications (2)

Publication Number Publication Date
WO2002000872A2 WO2002000872A2 (fr) 2002-01-03
WO2002000872A3 true WO2002000872A3 (fr) 2002-08-22

Family

ID=8851872

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2001/002058 WO2002000872A2 (fr) 2000-06-29 2001-06-28 Compositions et methodes pour le traitement ou la detection de pathologies neurodegeneratives

Country Status (3)

Country Link
AU (1) AU2001270691A1 (fr)
FR (1) FR2810995A1 (fr)
WO (1) WO2002000872A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2837838B1 (fr) * 2002-03-26 2005-01-28 Exonhit Therapeutics Sa Nouvelle cible moleculaire de la neurotoxicite
WO2003080864A1 (fr) * 2002-03-26 2003-10-02 Exhonit Therapeutics Sa Histone deacetylase: nouvelle cible moleculaire de la neurotoxicite
TW200407160A (en) * 2002-10-08 2004-05-16 Kazuhito Tomizawa Inhibitors for continuous activation of calcineurin
EP1810675A1 (fr) * 2006-01-18 2007-07-25 Institut Curie Methode de traitement de la maladie de Huntington par l'inhibition de la dephosphorylation de la S421
US20180085356A1 (en) * 2013-05-24 2018-03-29 Chronos Therapeutics Limited Method of treating disease characterised by protein aggregate deposition in neuronal cells
GB201309375D0 (en) * 2013-05-24 2013-07-10 Chronos Therapeutics Ltd Medical methods and compounds for medical use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898029A (en) * 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
WO1999065450A2 (fr) * 1998-06-18 1999-12-23 Massachusetts Institute Of Technology Agents immunosuppresseurs inhibant la fonction calcineurine et utilisations de ceux-ci

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5898029A (en) * 1994-04-12 1999-04-27 The John Hopkins University Direct influences on nerve growth of agents that interact with immunophilins in combination with neurotrophic factors
WO1999065450A2 (fr) * 1998-06-18 1999-12-23 Massachusetts Institute Of Technology Agents immunosuppresseurs inhibant la fonction calcineurine et utilisations de ceux-ci

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
AIT-IKHLEF A ET AL: "Identification of splice variants in Amyotrophic Lateral Sclerosis using a new technology: DATAS.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 27, no. 2, 2001, 31st Annual Meeting of the Society for Neuroscience;San Diego, California, USA; November 10-15, 2001, pages 1649, XP002201672, ISSN: 0190-5295 *
ANKARCRONA MARIA ET AL: "Calcineurin and mitochondrial function in glutamate-induced neuronal cell death.", FEBS LETTERS, vol. 394, no. 3, 1996, pages 321 - 324, XP002162575, ISSN: 0014-5793 *
GARVER TIMOTHY D ET AL: "Reduction of calcineurin activity in brain by antisense oligonucleotides leads to persistent phosphorylation of tau protein at Thr181 and Thr231.", MOLECULAR PHARMACOLOGY, vol. 55, no. 4, April 1999 (1999-04-01), pages 632 - 641, XP002162574, ISSN: 0026-895X *
LEE JEAN-PYO ET AL: "The role of immunophilins in mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 96, no. 6, 16 March 1999 (1999-03-16), March 16, 1999, pages 3251 - 3256, XP002162573, ISSN: 0027-8424 *
PERRINO BRIAN A: "Regulation of calcineurin phosphatase activity by its autoinhibitory domain.", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, vol. 372, no. 1, 1 December 1999 (1999-12-01), pages 159 - 165, XP002162576, ISSN: 0003-9861 *
PRICE D L ET AL: "Amyotrophic lateral sclerosis and Alzheimer's disease. Lessons from model systems.", REVUE NEUROLOGIQUE (PARIS), vol. 153, no. 8-9, 1997, pages 484 - 495, XP000982876, ISSN: 0035-3787 *
RESINK A M ET AL: "DATAS opens new avenues to drug development in neurodegenerative disease.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, 30th Annual Meeting of the Society of Neuroscience;New Orleans, LA, USA; November 04-09, 2000, pages Abstract No. - 94.20, XP002201671, ISSN: 0190-5295 *
REUTER A T ET AL: "Changes of calcineurin isoform expression levels in a mouse model of amyotrophic lateral sclerosis.", SOCIETY FOR NEUROSCIENCE ABSTRACTS, vol. 26, no. 1-2, 2000, 30th Annual Meeting of the Society of Neuroscience;New Orleans, LA, USA; November 04-09, 2000, pages Abstract No. - 572.17, XP002162577, ISSN: 0190-5295 *
VOELKEL H ET AL: "Expression of calcineurin-A-alpha is reduced in the spinal cord of mice transgenic for mutated copper/zinc superoxide dismutase.", SOCIETY FOR NEUROSCIENCE ABSTRACTS., vol. 25, no. 1-2, 1999, 29th Annual Meeting of the Society for Neuroscience.;Miami Beach, Florida, USA; October 23-28, 1999, pages 1304, XP000982893, ISSN: 0190-5295 *

Also Published As

Publication number Publication date
AU2001270691A1 (en) 2002-01-08
FR2810995A1 (fr) 2002-01-04
WO2002000872A2 (fr) 2002-01-03

Similar Documents

Publication Publication Date Title
WO2003016563A3 (fr) Cible moleculaire de la neurotoxicite
WO2005065195A3 (fr) Inhibiteurs de phenylamide et de pyridylamide de la beta-secretase, traitant la maladie d'alzheimer
WO2004062625A3 (fr) Inhibiteurs de beta-secretase macrocyclique pour traiter la maladie d'alzheimer
WO2005004803A3 (fr) Inhibiteurs de la beta-secretase de phenylcarboxylate destines au traitement de la maladie d'alzheimer
WO2001070944A3 (fr) Nematodes utilises comme organismes modeles servant a etudier des maladies neurodegeneratives, notamment la maladie de parkinson, et procede pour deceler des substances et des genes qui peuvent etre utilises pour le traitement de ces maladies, et identification d'un gene de nematode.
WO2005004802A3 (fr) Inhibiteurs de la beta-secretase a base de n-alkyle phenylcarboxamide pour le traitement de la maladie d'alzheimer
AU2989300A (en) Controlling protein levels in eucaryotic organisms
WO1998007850A3 (fr) Agents pour la detection pre-symptomatique et le ciblage therapeutique de la maladie d'alzheimer et du syndrome de down chez l'homme
WO2005018545A3 (fr) Inhibiteurs macrocycliques de la beta-secretase destines au traitement de la maladie d'alzheimer
WO2005032471A3 (fr) Inhibiteurs de type benzylether et benzylamino de beta-secretase pour le traitement de la maladie d'alzheimer
WO2001070977A3 (fr) Molecules analogues au recepteur du facteur de croissance du fibroblaste, et leurs utilisations
WO2003039540A3 (fr) Inhibiteurs de d-amino acide oxydase destines a l'apprentissage et a la memoire
WO2010011283A3 (fr) Composés à base de fus/tls et méthodes de diagnostic, traitement et prévention d'une sclérose latérale amyotrophique et de maladies des motoneurones apparentées
AU7408301A (en) Novel target genes for diseases of the heart
WO2002000872A3 (fr) Compositions et methodes pour le traitement ou la detection de pathologies neurodegeneratives
WO1999051186A3 (fr) Procedes et compositions destines au diagnostic et au traitement de troubles neuropsychiatriques
WO2002046767A3 (fr) Molecules d'acide nucleique, polypeptides et utilisations associees, parmi lesquelles diagnostic et traitement de la maladie d'alzheimer
WO2003076610A3 (fr) Variants de kallikrein-2 et kallikrein-3 humaines et leurs utilisations
WO2006025995A3 (fr) Compositions et methodes faisant intervenir des mutants md-2 et des proteines chimeres
WO2000023587A3 (fr) Therapie genique de la maladie d'alzheimer par administration d'une apolipoproteine e codee
WO2003087325A3 (fr) Methodes et compositions de prevention et de traitement d'infections microbiennes
WO2001096397A3 (fr) Variants cd154
WO1999002120A3 (fr) Compositions et methodes permettant d'augmenter la permeabilite de bio-membranes
WO2001064876A3 (fr) Gene humain de la schizophrenie
WO2001051489A3 (fr) Procedes pour abaisser les niveaux d'acide urique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP